Antitumor activity of an engineered decoy receptor targeting CLCF1–CNTFR signaling in lung adenocarcinoma

Journal: Nature Medicine

Published: 2019-11-07

DOI: 10.1038/s41591-019-0612-2

Affiliations: 14

Authors: 16

Go to article
Institutions Share
UCSF Department of Pediatrics, United States of America (USA) 0.26
UCSF Division of Hematology and Medical Oncology, United States of America (USA) 0.26
Stanford Department of Bioengineering, United States of America (USA) 0.13
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Spain 0.06
Stanford Department of Neurosurgery, United States of America (USA) 0.06
Healthcare Research Institute (i+12), Spain 0.04
H12O-CNIO Lung Cancer Clinical Research Unit, CNIO, Spain 0.04
Stanford School of Medicine, United States of America (USA) 0.04
Stanford Department of Surgery, United States of America (USA) 0.03
Stanford Division of Thoracic Surgery, United States of America (USA) 0.03
Center for Applied Medical Research (CIMA), UNAV, Spain 0.02
Departamento de Histología y Anatomía Patológica, UNAV, Spain 0.02
Stanford Department of Comparative Medicine, United States of America (USA) 0.02

Return

Except where otherwise noted © 2021 Springer Nature Limited. All Rights Reserved.
partner of AGORA, HINARI, OARE, INASP, ORCID, CrossRef and COUNTER